ICUI Earnings

ICUI reported its earnings on 2026-05-07, showcasing a revenue of 530.23M against an estimate of 519.93M, resulting in a 1.98% surprise. The EPS was 1.97, surpassing the expected 1.75 by 48.12%. The stock experienced a 2.73% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ICUI's earnings announcement on 2026-05-07, the stock price moved by 2.73% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, ICUI's stock price tends to shift by an average of -0.19% in the 10 days leading up to earnings and -2.93% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate ICUI's annual revenue to reach 537.60M, while the EPS is projected at 0.34. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ICUI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ICUI's stock price typically moves by -0.19% in the 10 days before its earnings and -2.93% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.34 and revenue of 537.60M.

The earnings call presents a mixed picture. While there is strong performance in IV Systems and consistent guidance for EBITDA and EPS, the decline in Vital Care revenue and management's vague responses about certain issues could cause investor uncertainty. The company's focus on reducing debt and maintaining higher price points is positive, but the lack of immediate financial impact from new hardware and unresolved issues in Vital Care tempers optimism. The market cap suggests moderate volatility, leading to a neutral prediction for the stock price movement.